Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trial
Results for the completed 228-patient trial comparing ONS-5010 to ranibizumab in neovascular AMD were posted on ClinicalTrials.gov as of August 3, 2026.
Outlook Therapeutics posted results this week for a completed Phase 3 study of its investigational bevacizumab formulation ONS-5010.
- The trial, registered as NCT03834753, tested ONS-5010 against ranibizumab in participants with subfoveal choroidal neovascularization secondary to age-related macular degeneration, aiming to evaluate whether ONS-5010 could prevent vision loss compared with ranibizumab.1 The study enrolled 228 participants and was designed as a randomized, phase 3 trial.1
- On the primary endpoint, 45 participants on bevacizumab and 24 on ranibizumab gained 15 or more letters in best corrected visual acuity.1 Serious adverse events were reported in 14 of 113 bevacizumab-treated participants and 16 of 115 ranibizumab-treated participants.1
- The study reached primary completion on June 7, 2021, and study completion on July 8, 2021,1 with results first posted on August 3, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.